论文部分内容阅读
目的观察乌司他丁治疗重度慢性阻塞性肺疾病(COPD)急性发作期的临床疗效。方法采用随机数字表法将重度COPD急性发作期患者76例分为治疗组和对照组各38例。2组患者均给予吸氧、β受体激动剂、糖皮质激素吸入、补液、维持水电解质平衡及抗菌药物治疗,治疗组在此基础上加用乌司他丁注射液治疗。观察2组治疗前后COPD患者自我评估测试(CAT评分)、一秒用力呼气容积占用力肺活量比值(FEV1%)、动脉血氧分压(Pa O2)、超敏C反应蛋白(hs-CRP)、降钙素原(PCT)水平的变化。结果 2组患者治疗后1周CAT评分低于治疗前,FEV1%及Pa O2高于治疗前,且治疗组变化幅度明显大于对照组;2组患者治疗后1周hs-CRP及PCT水平均低于治疗前,且治疗组明显低于对照组,差异均有统计学意义(P<0.05)。结论乌司他丁能显著缓解重度COPD急性发作期患者的临床症状,改善肺部功能,促进病情恢复。
Objective To observe the clinical efficacy of ulinastatin in the treatment of acute exacerbation of severe chronic obstructive pulmonary disease (COPD). Methods A random number table method was used to divide 76 patients with acute COPD exacerbation into 38 cases in the treatment group and 38 cases in the control group. Both groups were given oxygen inhalation, β-agonist, glucocorticoid inhalation, rehydration, maintaining water and electrolyte balance and antimicrobial treatment, the treatment group on this basis with ulinastatin injection. The results of self-assessment test (CAT score), FEV1%, Pa O2 and hs-CRP of COPD patients before and after treatment in two groups were observed. , Procalcitonin (PCT) level changes. Results The CAT scores of the two groups were lower than those before treatment, FEV1% and Pa O2 were higher than those before treatment, and the changes in the treatment group were significantly greater than those in the control group. The levels of hs-CRP and PCT in the two groups were lower Before treatment, and the treatment group was significantly lower than the control group, the difference was statistically significant (P <0.05). Conclusion Ulinastatin can significantly relieve the clinical symptoms of patients with severe COPD in acute episode, improve lung function and promote the recovery of the disease.